At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed and Cisplatin in Patients With Stage IV Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Pemetrexed, Cisplatin, and 1 other intervention for Non Small Cell Lung Cancer. Completed, enrolled 76 participants across 24 sites in 2 countries.
Detailed Summary
LY2603618 is a selective inhibitor of the deoxyribonucleic acid (DNA) damage checkpoint kinase 1 (CHK1). It was being developed as a chemotherapeutic-enhancing agent in the treatment of cancer. Phase 1 studies have shown the feasibility of combining LY2603618 with either gemcitabine or pemetrexed. The objective of this study was to find the dose of LY2603618 that can be safely combined with standard doses of pemetrexed and cisplatin and to test if this triplet offered a significant improvement in progression-free survival (PFS) in participants with Stage IV nonsquamous non-small cell lung cancer (NSCLC) in the first-line of palliative treatment.
Study Details
Timeline
Interventions
Administered intravenously as a continuous 10-minute infusion
Administered intravenously as a continuous 1-hour infusion
Administered intravenously as a continuous 1-hour infusion